Lymphoplasmacytic Enteritis

Lymphoplasmacytic enteritis (LPE) is a chronic inflammatory bowel disease (IBD) of the small intestine characterized by infiltration of the lamina propria and, in some cases, the submucosa and epithelium with lymphocytes and plasma cells. It is the most common form of IBD in dogs and cats, representing a spectrum of disease ranging from mild, subclinical inflammation to severe, protein-losing enteropathy (PLE). The condition is defined by histopathologic findings on intestinal biopsy, with the hallmark being an increased number of lymphocytes and plasma cells within the intestinal mucosa, often accompanied by architectural changes such as villus blunting, crypt hyperplasia, and fibrosis in chronic cases. LPE is a diagnosis of exclusion, requiring the elimination of other causes of chronic enteropathy, including dietary intolerance, infectious agents, and intestinal lymphoma. The disease can affect any segment of the small intestine, but the duodenum and jejunum are most commonly involved. In cats, LPE is frequently associated with concurrent cholangitis and pancreatitis, forming the 'triaditis' complex. The clinical significance of LPE lies in its potential to cause chronic diarrhea, weight loss, vomiting, and, in severe cases, hypoalbuminemia and ascites due to protein loss. The pathogenesis involves a dysregulated immune response to dietary and microbial antigens in genetically susceptible individuals, leading to chronic mucosal inflammation. Treatment typically involves immunosuppressive therapy, dietary modification, and supportive care, with a variable prognosis depending on the severity of inflammation and the presence of complications such as PLE or concurrent neoplasia.

The exact etiology of lymphoplasmacytic enteritis is not fully understood, but it is considered a multifactorial disease involving an aberrant immune response to commensal gut flora and dietary antigens in genetically predisposed individuals. Several potential triggers have been identified: 1) Dietary antigens: Proteins, carbohydrates, and additives in commercial diets can act as antigens, triggering an inappropriate mucosal immune response. In dogs, adverse food reactions are a common cause of chronic enteropathy, and a subset of LPE cases responds to dietary elimination trials. 2) Intestinal microbiota: Dysbiosis, an alteration in the composition and function of the gut microbiome, has been documented in dogs and cats with IBD. Changes in bacterial populations, such as increased Enterobacteriaceae and decreased Clostridiales, can promote inflammation through the activation of Toll-like receptors (TLRs) and the production of pro-inflammatory cytokines. 3) Genetic susceptibility: Certain breeds, such as German Shepherds, Boxers, and Yorkshire Terriers, have a higher incidence of IBD, suggesting a genetic component. Polymorphisms in genes encoding for cytokines (e.g., TNF-α, IL-10) and pattern recognition receptors (e.g., NOD2) have been implicated. 4) Immunological dysregulation: A breakdown in oral tolerance, leading to an exaggerated Th1 and Th17 response, with a relative deficiency of regulatory T cells (Tregs), results in chronic inflammation. Increased production of pro-inflammatory cytokines (TNF-α, IFN-γ, IL-12, IL-17) and decreased anti-inflammatory cytokines (IL-10, TGF-β) have been observed. 5) Infectious agents: Although no specific pathogen has been consistently isolated, some studies have suggested a role for bacteria such as Escherichia coli, Salmonella, and Campylobacter, as well as protozoa like Giardia and Tritrichomonas, in triggering or perpetuating inflammation. 6) Environmental factors: Stress, poor husbandry, and concurrent diseases (e.g., chronic pancreatitis, cholangitis) may contribute to the development or exacerbation of LPE. 7) Idiopathic: In many cases, no specific trigger can be identified, and the disease is classified as idiopathic.

Lymphoplasmacytic enteritis is the most common histopathologic diagnosis in dogs and cats with chronic gastrointestinal signs. It accounts for approximately 50-60% of canine IBD cases and up to 70% of feline IBD cases. The disease can occur in any breed, but certain breeds are overrepresented: in dogs, German Shepherds, Boxers, Yorkshire Terriers, and Rottweilers are at increased risk; in cats, Siamese and other purebred cats may be predisposed. There is no clear sex predilection, though some studies suggest a slight female predominance in cats. The age of onset is typically middle-aged to older animals, with a mean age of 6-8 years in dogs and 7-9 years in cats, but cases have been reported in young animals. The incidence is higher in indoor cats, possibly due to dietary and environmental factors. Geographic variation is not well-documented, but the disease is seen worldwide. The prevalence of LPE appears to be increasing, possibly due to improved diagnostic techniques and increased awareness. In cats, LPE is often part of triaditis, with concurrent cholangitis and pancreatitis, which may complicate the clinical picture. The disease is chronic and progressive, with many animals requiring long-term management.

The pathophysiology of lymphoplasmacytic enteritis involves a complex interplay between the intestinal mucosal immune system, the gut microbiome, and dietary antigens. In genetically susceptible individuals, a breakdown in oral tolerance leads to an inappropriate immune response. The intestinal epithelium, which normally acts as a barrier, becomes more permeable due to disruption of tight junctions, allowing luminal antigens to penetrate the lamina propria. This triggers an innate immune response via pattern recognition receptors (e.g., TLRs) on epithelial cells and dendritic cells, leading to the activation of nuclear factor kappa B (NF-κB) and the production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). Antigen-presenting cells (APCs) then present antigens to naïve T cells, promoting differentiation into Th1 and Th17 effector cells. These cells secrete cytokines (IFN-γ, IL-17) that activate macrophages and recruit additional inflammatory cells, including lymphocytes and plasma cells, into the mucosa. The chronic inflammatory infiltrate leads to tissue damage, villus blunting, crypt hyperplasia, and eventually fibrosis. The loss of absorptive surface area results in malabsorption and maldigestion, leading to diarrhea and weight loss. In severe cases, the inflamed mucosa becomes leaky to proteins, leading to protein-losing enteropathy (PLE), characterized by hypoalbuminemia, panhypoproteinemia, and, in some cases, ascites and peripheral edema. Additionally, the chronic inflammation can lead to a hypercoagulable state, increasing the risk of thromboembolism. In cats, the inflammatory process may extend to the biliary tract and pancreas, resulting in triaditis. The disease can also progress to intestinal lymphoma, particularly in cats, where the distinction between severe LPE and low-grade lymphoma can be challenging.

Several factors predispose animals to the development of lymphoplasmacytic enteritis: 1) Genetic predisposition: Certain breeds (e.g., German Shepherds, Boxers, Yorkshire Terriers, Siamese cats) have a higher risk, suggesting a heritable component. 2) Age: Middle-aged to older animals are more commonly affected, though young animals can also develop the disease. 3) Diet: Feeding of highly processed diets, food allergies, or intolerances to specific proteins (e.g., beef, dairy, chicken) can trigger or exacerbate inflammation. 4) Intestinal dysbiosis: Alterations in the gut microbiome, often due to antibiotic use, dietary changes, or stress, can promote inflammation. 5) Concurrent diseases: Chronic pancreatitis, cholangitis (in cats), and exocrine pancreatic insufficiency can predispose to or coexist with LPE. 6) Immunosuppression: Animals on long-term immunosuppressive therapy (e.g., corticosteroids) may be at increased risk due to altered immune regulation. 7) Environmental stress: Changes in environment, boarding, or other stressors can precipitate clinical signs. 8) Infectious agents: Prior or concurrent infections with Giardia, Tritrichomonas, or bacterial pathogens may trigger the inflammatory response. 9) Medications: Non-steroidal anti-inflammatory drugs (NSAIDs) and other drugs that disrupt the intestinal barrier may increase susceptibility.

Clinical signs of lymphoplasmacytic enteritis are typically chronic and progressive, with a duration of weeks to months. The most common signs include: 1) Chronic diarrhea: Often small-bowel diarrhea, characterized by large volume, watery or semi-formed stools, with or without mucus, and typically without blood. In some cases, large-bowel diarrhea (tenesmus, hematochezia) may be present if the colon is also involved. 2) Weight loss: Due to malabsorption and increased metabolic demands. 3) Vomiting: More common in cats, often intermittent and may contain bile or foam. 4) Decreased appetite: Anorexia or hyporexia is common, especially in cats. 5) Abdominal discomfort: Mild to moderate pain on palpation, often due to thickened bowel loops. 6) Borborygmus and flatulence: Due to altered motility and fermentation. 7) Lethargy: Reduced activity level. 8) In severe cases with PLE: Peripheral edema, ascites, and pleural effusion due to hypoalbuminemia. 9) In cats with triaditis: Icterus, fever, and signs of pancreatitis (e.g., cranial abdominal pain). Physical examination may reveal thin body condition, poor hair coat, thickened intestinal loops on abdominal palpation, and, in cases of PLE, ascites or edema. In some animals, no significant abnormalities are found on physical examination.

The differential diagnoses for lymphoplasmacytic enteritis include: 1) Food-responsive enteropathy (FRE): A chronic enteropathy that responds to dietary elimination trials. Key features: Clinical signs similar to LPE, but histopathology may show mild or no inflammation. Diagnosis is made by response to a novel protein or hydrolyzed diet. Rule out by performing a strict dietary trial for 2-4 weeks; if signs resolve, FRE is likely. 2) Antibiotic-responsive enteropathy (ARE): Also known as antibiotic-responsive diarrhea, often due to small intestinal bacterial overgrowth (SIBO) or dysbiosis. Key features: Response to antibiotics such as tylosin or metronidazole. Diagnosis is based on clinical response; histopathology may show mild inflammation. Rule out by a trial of antibiotics (e.g., tylosin 10-20 mg/kg PO q12h) for 2-4 weeks. 3) Intestinal lymphoma: Especially in cats, low-grade lymphoma can mimic LPE clinically and histopathologically. Key features: Weight loss, vomiting, diarrhea, and thickened bowel loops. Histopathology may show dense infiltration of neoplastic lymphocytes, but differentiation can be difficult; immunophenotyping (B-cell vs. T-cell) and clonality testing (PCR for antigen receptor rearrangement) are helpful. Rule out by biopsy with immunohistochemistry and PCR. 4) Eosinophilic enteritis: A form of IBD characterized by eosinophilic infiltration. Key features: Peripheral eosinophilia may be present; histopathology shows eosinophilic infiltrate. Rule out by biopsy. 5) Granulomatous enteritis: Rare, often associated with fungal or mycobacterial infections. Key features: Granulomas on histopathology, special stains for organisms. Rule out by biopsy and culture. 6) Protein-losing enteropathy (PLE) due to other causes: Such as intestinal lymphangiectasia, which can coexist with LPE or occur independently. Key features: Severe hypoalbuminemia, lymphopenia, and dilated lacteals on histopathology. Rule out by biopsy. 7) Chronic pancreatitis and exocrine pancreatic insufficiency (EPI): Can cause similar signs. Key features: EPI is diagnosed by serum trypsin-like immunoreactivity (TLI) < 2.5 µg/L in dogs; pancreatitis by elevated pancreatic lipase immunoreactivity (PLI). Rule out by specific testing. 8) Parasitic infections: Giardiasis, trichomoniasis, and other parasites can cause chronic diarrhea. Key features: Fecal examination (direct smear, zinc sulfate flotation, or PCR) may identify organisms. Rule out by fecal testing and response to antiparasitic therapy. 9) Inflammatory bowel disease (other forms): Such as lymphocytic-plasmacytic colitis, which may involve the large intestine. Key features: Large-bowel diarrhea, colonic thickening on imaging. Rule out by colonoscopy and biopsy. 10) Chronic enteropathy due to adverse drug reactions: e.g., NSAID-induced enteropathy. Key features: History of drug administration. Rule out by history and withdrawal of the drug.

The diagnostic approach to lymphoplasmacytic enteritis is stepwise and aims to exclude other causes of chronic enteropathy. 1) Initial evaluation: Complete history and physical examination. 2) Minimum database: Complete blood count (CBC), serum biochemistry profile, urinalysis, and fecal examination (direct smear, flotation, and Giardia antigen test). These tests help rule out systemic diseases and parasitic infections. 3) Serum biomarkers: Measurement of cobalamin (vitamin B12) and folate levels; low cobalamin is common in LPE due to ileal disease. Also, measurement of pancreatic lipase immunoreactivity (PLI) to rule out pancreatitis. 4) Imaging: Abdominal radiographs may be unremarkable or show gas-filled loops. Abdominal ultrasound is more useful, revealing thickened small intestinal walls, loss of normal layering, and mesenteric lymphadenopathy. Ultrasound-guided fine-needle aspiration of thickened bowel or lymph nodes may be performed, but cytology is often inconclusive. 5) Dietary trial: A strict elimination diet (novel protein or hydrolyzed) for 2-4 weeks is recommended. If clinical signs resolve, a diagnosis of food-responsive enteropathy is made, and biopsy may be avoided. 6) Antibiotic trial: If no response to diet, a trial with tylosin or metronidazole for 2-4 weeks may be considered to rule out antibiotic-responsive enteropathy. 7) Endoscopy and biopsy: If there is no response to dietary or antibiotic trials, or if the animal is severely affected, endoscopic evaluation of the stomach, duodenum, and colon is indicated. Multiple biopsies (at least 6-8 from the duodenum) should be obtained. Histopathology is the gold standard for diagnosis. 8) Additional testing: In cats, serum fPLI and liver enzymes should be checked to assess for triaditis. If lymphoma is suspected, immunophenotyping and clonality testing on biopsy samples are recommended. 9) Advanced imaging: In cases where endoscopic biopsy is not possible or is non-diagnostic, full-thickness surgical biopsy may be necessary. 10) Genetic testing: Not routinely performed but may be considered in breeds with known predispositions.

Laboratory findings in lymphoplasmacytic enteritis are often non-specific but can support the diagnosis and assess severity. 1) Hematology: CBC may be normal, but mild anemia (non-regenerative) can occur due to chronic inflammation or blood loss. Lymphopenia may be present in severe cases, especially with PLE. Eosinophilia may be seen in some cases, but is more typical of eosinophilic enteritis. 2) Serum biochemistry: Hypoalbuminemia is a key finding in severe LPE with PLE; total protein may also be low. Globulins may be normal or elevated. Liver enzymes (ALT, ALP) may be mildly elevated, especially in cats with triaditis. Electrolyte disturbances, such as hypokalemia and hyponatremia, can occur due to diarrhea and vomiting. Cholesterol may be low in PLE. 3) Urinalysis: Usually unremarkable, but proteinuria may be present if there is concurrent glomerular disease. 4) Blood gas analysis: Metabolic acidosis may be present due to bicarbonate loss in diarrhea. 5) Specific biomarkers: Serum cobalamin (vitamin B12) is often decreased due to ileal disease; folate may be decreased or increased depending on the segment affected. Pancreatic lipase immunoreactivity (PLI) is normal in LPE but elevated in pancreatitis. C-reactive protein (CRP) may be elevated in dogs with IBD. In cats, fPLI is useful to rule out pancreatitis. 6) Serology/PCR: Fecal PCR panels for infectious agents (e.g., Giardia, Tritrichomonas, Salmonella, Campylobacter) may be performed to rule out infectious causes. 7) Endocrine assays: Thyroid and adrenal function tests may be considered to rule out endocrinopathies that can cause gastrointestinal signs.

Imaging plays a supportive role in the diagnosis of lymphoplasmacytic enteritis. 1) Abdominal radiography: Often unremarkable, but may show gas-filled small intestinal loops, which is non-specific. In cases of PLE, loss of serosal detail due to ascites may be seen. 2) Abdominal ultrasonography: This is the most useful imaging modality. Findings include: - Thickening of the small intestinal wall (normal duodenal wall thickness in dogs is < 5 mm; in cats < 2.5 mm). - Loss of normal layering (especially the mucosal layer). - Increased echogenicity of the mucosa. - Mesenteric lymphadenopathy (enlarged, hypoechoic lymph nodes). - In cats, concurrent changes in the liver (biliary tract dilation, increased echogenicity) and pancreas (enlarged, hypoechoic) may be seen, supporting triaditis. - Doppler ultrasound may show increased blood flow to the affected bowel. 3) Computed tomography (CT): Not routinely used, but may be helpful in assessing the extent of disease and for surgical planning. 4) Magnetic resonance imaging (MRI): Rarely used, but can provide detailed images of the intestinal wall. 5) Endoscopy: Allows direct visualization of the mucosa, which may appear erythematous, friable, or thickened. However, endoscopic findings are not specific, and biopsy is required. 6) Fluoroscopy: May be used to assess motility, but is not diagnostic for LPE.

Cytology and histopathology are essential for the diagnosis of lymphoplasmacytic enteritis. 1) Fine-needle aspiration (FNA): Ultrasound-guided FNA of thickened bowel loops or mesenteric lymph nodes may be performed. Cytology of the intestine is often non-diagnostic due to the difficulty in obtaining representative samples and the presence of mixed inflammatory cells. However, FNA of lymph nodes may reveal reactive hyperplasia or, in cases of lymphoma, neoplastic lymphocytes. 2) Histopathology: Endoscopic or surgical biopsies are the gold standard. Histopathologic features include: - Increased numbers of lymphocytes and plasma cells in the lamina propria, often with a mixed inflammatory infiltrate (eosinophils, macrophages) in some cases. - Villus blunting and fusion. - Crypt hyperplasia and distortion. - Fibrosis of the lamina propria in chronic cases. - Epithelial damage, such as enterocyte attenuation or erosion. - In severe cases, lacteal dilation (lymphangiectasia) may be present. - Grading systems (e.g., the World Small Animal Veterinary Association (WSAVA) guidelines) are used to standardize the assessment of inflammation and architectural changes. - Immunohistochemistry (IHC) can be used to differentiate between reactive lymphocytes and neoplastic lymphocytes (e.g., CD3 for T-cells, CD79a for B-cells). - Clonality testing (PCR for antigen receptor rearrangement) can help distinguish between inflammatory and neoplastic infiltrates, especially in cats.

Treatment of lymphoplasmacytic enteritis is multimodal and aims to reduce inflammation, manage clinical signs, and address complications. 1) Emergency stabilization: In severe cases with dehydration, hypovolemia, or electrolyte imbalances, intravenous fluid therapy with balanced crystalloids (e.g., Lactated Ringer's solution) is initiated. Potassium supplementation may be needed. In cases of PLE with severe hypoalbuminemia (< 1.5 g/dL), colloids (e.g., hetastarch) or plasma transfusions may be considered, though their use is controversial. 2) Dietary management: A highly digestible, low-residue diet is recommended. In cases of food-responsive enteropathy, a novel protein or hydrolyzed diet is used. For LPE, a diet with moderate fat restriction may be beneficial, especially if there is concurrent lymphangiectasia. Omega-3 fatty acid supplementation (e.g., eicosapentaenoic acid 40 mg/kg/day) may have anti-inflammatory effects. 3) Immunosuppressive therapy: - Corticosteroids: Prednisolone is the first-line immunosuppressive agent. In dogs, the initial dose is 1-2 mg/kg PO q12h, tapered over 4-6 weeks. In cats, prednisolone is preferred over prednisone due to better absorption; dose is 1-2 mg/kg PO q12h. In severe cases, a higher dose (up to 3 mg/kg/day) may be used. - Budesonide: A locally acting corticosteroid with fewer systemic side effects, used in dogs at 1-2 mg/dog PO q24h, and in cats at 1 mg/cat PO q24h. It may be considered for animals that do not tolerate systemic steroids. - Azathioprine: An immunosuppressive agent used as a steroid-sparing drug. In dogs, dose is 2 mg/kg PO q24h or q48h; in cats, 0.3-0.5 mg/kg PO q48h. It takes 4-6 weeks to achieve full effect. - Chlorambucil: Used in cats with severe LPE or when steroids are ineffective. Dose is 2-4 mg/m² PO q48h or 0.1-0.2 mg/kg PO q24h. - Cyclosporine: May be used in dogs at 5-10 mg/kg PO q12h, and in cats at 5 mg/kg PO q24h. It is more expensive but has fewer long-term side effects. 4) Antibiotics: Metronidazole (10-15 mg/kg PO q12h) is commonly used for its immunomodulatory and antibacterial effects. Tylosin (10-20 mg/kg PO q12h) may be used for antibiotic-responsive diarrhea. 5) Antiemetics: If vomiting is present, maropitant (1 mg/kg SC q24h or 2 mg/kg PO q24h) or ondansetron (0.5-1 mg/kg IV or PO q12h) may be used. 6) Antidiarrheals: Loperamide (0.1-0.2 mg/kg PO q8h) may be used in dogs, but is contraindicated in cats. 7) Supportive care: Vitamin B12 (cobalamin) supplementation is often necessary, especially if serum levels are low. Dose: 250-500 µg SC or IM once weekly for 4-6 weeks, then monthly. Folic acid may also be supplemented. 8) Management of PLE: In addition to immunosuppression, anticoagulant therapy (e.g., low-dose aspirin or clopidogrel) may be considered to prevent thromboembolism. 9) Surgery: In cases of intestinal stricture or obstruction, surgical resection may be necessary. 10) Monitoring: Regular re-evaluation is essential to adjust therapy and monitor for adverse effects.

The prognosis for lymphoplasmacytic enteritis is variable and depends on the severity of disease, response to therapy, and presence of complications. In general, dogs and cats with mild to moderate LPE have a good prognosis, with many achieving clinical remission with appropriate treatment. However, the disease is chronic and often requires long-term management. Factors associated with a poorer prognosis include: - Severe hypoalbuminemia (< 1.5 g/dL) at diagnosis. - Presence of protein-losing enteropathy. - Lack of response to immunosuppressive therapy within 2-4 weeks. - Presence of concurrent diseases such as pancreatitis or cholangitis. - Development of intestinal lymphoma, especially in cats. - Histopathologic evidence of severe fibrosis or lymphangiectasia. Mortality rates are low, but some animals may require euthanasia due to refractory disease or complications. In cats, the prognosis is generally good, but the risk of progression to lymphoma is a concern. With appropriate management, many animals can have a good quality of life for years.

Follow-up care for lymphoplasmacytic enteritis is crucial for monitoring response to therapy and adjusting treatment. 1) Initial re-evaluation: 2-4 weeks after starting treatment to assess clinical response. 2) Serial laboratory monitoring: - Serum albumin and total protein should be monitored every 2-4 weeks until normalized. - CBC and biochemistry profile should be checked every 3-6 months to monitor for adverse effects of immunosuppressive drugs (e.g., bone marrow suppression, hepatotoxicity). - Serum cobalamin levels should be rechecked after 4-6 weeks of supplementation. 3) Imaging: Abdominal ultrasound may be repeated every 3-6 months to assess intestinal wall thickness and lymph node size. 4) Drug titration: Corticosteroid doses should be tapered gradually (e.g., 25% reduction every 2-4 weeks) to the lowest effective dose. If azathioprine or chlorambucil is used, CBC should be monitored every 2-4 weeks initially, then every 3 months. 5) Dietary management: Long-term dietary compliance is essential. 6) Owner education: Owners should be educated about the chronic nature of the disease and the importance of regular follow-up. 7) In cats, monitoring for signs of lymphoma (e.g., worsening clinical signs, new masses) is important.

Pearls: 1) Always perform a thorough diagnostic workup, including dietary and antibiotic trials, before committing to immunosuppressive therapy. 2) In cats, always consider triaditis and evaluate pancreatic and hepatic parameters. 3) Use prednisolone in cats, not prednisone, due to better bioavailability. 4) Cobalamin supplementation is often necessary and can significantly improve clinical signs. 5) In dogs with PLE, consider anticoagulant therapy to prevent thromboembolism. 6) Budesonide is a good alternative for animals that develop steroid side effects. 7) Histopathology is essential for diagnosis; do not rely on clinical signs alone. Pitfalls: 1) Failing to rule out infectious causes, especially Giardia, before starting immunosuppression. 2) Using prednisone in cats, which is less effective. 3) Tapering steroids too quickly, leading to relapse. 4) Overlooking the possibility of intestinal lymphoma, especially in cats; always consider immunophenotyping and clonality testing. 5) Not monitoring for adverse effects of immunosuppressive drugs. 6) Assuming that a lack of response to diet means the animal does not have food-responsive enteropathy; some animals require longer trials. 7) In cases of severe hypoalbuminemia, aggressive fluid therapy with crystalloids can worsen edema; use colloids cautiously.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are commonly used for lymphoplasmacytic enteritis: 1) Prednisolone (dogs): 1-2 mg/kg PO q12h for 2-4 weeks, then taper by 25% every 2-4 weeks to a maintenance dose of 0.5-1 mg/kg PO q48h. In cats: 1-2 mg/kg PO q12h, taper similarly. 2) Budesonide (dogs): 1-2 mg/dog PO q24h; (cats): 1 mg/cat PO q24h. 3) Azathioprine (dogs): 2 mg/kg PO q24h for 2-4 weeks, then q48h; (cats): 0.3-0.5 mg/kg PO q48h. Monitor CBC for myelosuppression. 4) Chlorambucil (cats): 2-4 mg/m² PO q48h or 0.1-0.2 mg/kg PO q24h. 5) Cyclosporine (dogs): 5-10 mg/kg PO q12h; (cats): 5 mg/kg PO q24h. Monitor trough levels if possible. 6) Metronidazole: 10-15 mg/kg PO q12h for 2-4 weeks. 7) Tylosin: 10-20 mg/kg PO q12h for 2-4 weeks. 8) Maropitant: 1 mg/kg SC q24h or 2 mg/kg PO q24h for vomiting. 9) Ondansetron: 0.5-1 mg/kg IV or PO q12h. 10) Cobalamin (vitamin B12): 250-500 µg SC or IM once weekly for 4-6 weeks, then monthly. 11) Omega-3 fatty acids: EPA 40 mg/kg/day PO. 12) For PLE: Consider low-dose aspirin (0.5-1 mg/kg PO q24h) or clopidogrel (1-2 mg/kg PO q24h) for anticoagulation. All doses should be adjusted based on renal or hepatic function, and drug interactions should be considered (e.g., azathioprine with allopurinol).

Evidence-based literature on lymphoplasmacytic enteritis includes: 1) ACVIM consensus statement on the diagnosis and treatment of chronic inflammatory enteropathy in dogs and cats (2010) provides guidelines for diagnosis and management. 2) Studies by Jergens et al. (2003) and others have evaluated the use of histopathologic grading systems (WSAVA) to standardize diagnosis. 3) A study by Allenspach et al. (2007) found that hypoalbuminemia and severe histologic lesions are negative prognostic indicators in dogs with IBD. 4) In cats, a study by Kiselow et al. (2008) showed that cats with LPE have a good response to prednisolone and chlorambucil, but a subset may develop lymphoma. 5) Research on the gut microbiome in canine IBD (e.g., Suchodolski et al., 2012) has identified dysbiosis as a key factor, leading to the use of probiotics and fecal transplantation as potential therapies. 6) A randomized controlled trial by Craven et al. (2004) compared prednisolone and budesonide in dogs with IBD, showing similar efficacy but fewer side effects with budesonide. 7) Studies on cobalamin supplementation (e.g., Kather et al., 2010) have demonstrated improved clinical outcomes in dogs and cats with hypocobalaminemia. 8) The use of cyclosporine in dogs with IBD has been evaluated in a study by Allenspach et al. (2006), showing efficacy as a rescue therapy. 9) In cats, the triaditis complex has been described in several studies (e.g., Weiss et al., 1996), emphasizing the need for a comprehensive approach. 10) Recent advances in molecular diagnostics, such as PCR for antigen receptor rearrangement (PARR), have improved the differentiation between IBD and lymphoma (e.g., Moore et al., 2005). Overall, the evidence supports a stepwise approach to diagnosis and the use of immunosuppressive therapy with dietary modification for the management of LPE.